Work

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer

Year: 2017

Type: article

Study design: Clinical Trial

Source: Clinical Breast Cancer

DOI: 10.1016/j.clbc.2017.10.014

Authors: Autumn J. McRee, Paul K. Marcom, Dominic T. Moore, William C. Zamboni, Zachary A. Kornblum, Zhiyuan Hu, Rachel Phipps, Carey K. Anders, Katherine Reeder-Hayes, Lisa A. Carey, Karen E. Weck, Charles M. Perou, E. Claire Dees

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Duke Medical Center, Duke Cancer Institute

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Susan G. Komen for the Cure, Eli Lilly and Company, Pfizer, Sanofi, Novartis Pharmaceuticals Corporation, Susan G. Komen, Puma Biotechnology, Genentech, National Cancer Institute

Awards: G108258030, G1569999668, G2407663899, G6678531811, G870117454, Cancer Center Support Grant

OpenAlex ID: W2765367174

FWCI: 3.036

Cites: 28

Cited by: 30

Related to: 10